Chinese vaccine successfully enters third phase of clinical trial

China National Biotech Group announces that one of its inactive vaccines has a satisfactory antibody response in the first and second phases of its trial and has entered its third stage.

In previous stages, the bodies of all volunteers produced antibodies after receiving the vaccine, a result that could raise hopes for the discovery of the corona vaccine.

According to one of the project’s senior scientists, this is the first inactive vaccine in the world to enter clinical trials proving the safety and production of a high percentage of neutralizing antibodies.

After completing stages one and two of the clinical trial, the project’s executive company plans to start phase three abroad in the upcoming months, in fact, this phase will be done with the company’s foreign partners.

Last week, another Chinese pharmaceutical company ‘Sinovac’ based in Beijing announced that its anti-coronavirus vaccine triggered the production of the immune response in the bodies of volunteers.

-Chinese vaccines